Abstract: Objective To analyze the relationship between pathological features of NSCLC patients and serum high mobility group box 1 (HMGB 1) and programmed death 1 ligand 1 (PD-L1). Methods From 2016 to 2018, 78 NSCLC patients and 48 healthy volunteers were selected. The expression of serum HMGB 1 and PD-L1 was detected by ELISA, and the pathological characteristics of peripheral blood HMGB 1 and PD-L1 and NSCLC were analyzed. Results The serum HMGB 1 (6.89±1.58 ng/ml) and PD-L1 (389.3±68.5 pg/ml) in the NSCLC patients were increased (P<0.001) compared with the control (P<0.001). Comparision of HMGB 1 with PD-L1 in different pathological types of NSCLC indicated that both the serum levels of HMGB 1 and PD-L1 were gradually increased in phases I, II, III, and IV. HMGB 1 and PD-L1 were fund to be remarkably elevated in the patients with lymph node metastasis (P<0.05). Conclusion Detection of HMGB 1 and PD-L1 in the sera of NSCLC patients is clinically valuable for prediction of tumor invasiveness and prognosis.

Key words: Non-small cell lung cancer, HMGB 1, PD-L1